undamentalytics Newsletter
Sign in

Arcutis Biotherapeutics, Inc. cash flow statement

In fiscal 2025, Arcutis Biotherapeutics, Inc.'s operations generated −$5.6m of cash; it spent $686,000 on capital projects, leaving free cash flow of −$6.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−113−175−258−247−112−639
Depreciation and amortisation001111—
Stock-based pay8243339424044
Capital spending0100010
Free cash flow−113−176−258−247−112−639
Free cash flow after stock pay−121−200−291−286−154−47−4
Shares issued12820716201620—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ARQT vs CRMDARQT vs KRYSARDX vs ARQTADMA vs ARQT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arcutis Biotherapeutics, Inc.